Allergy Therapeutics

We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.
Type
Public
HQ
Worthing, GB
Founded
1934
Size (employees)
440 (est)+18%
Allergy Therapeutics was founded in 1934 and is headquartered in Worthing, GB

Allergy Therapeutics Office Locations

Allergy Therapeutics has an office in Worthing
Worthing, GB (HQ)
Dominion Way

Allergy Therapeutics Financials and Metrics

Allergy Therapeutics Financials

Allergy Therapeutics's revenue was reported to be £48.5 m in FY, 2016 which is a 12% increase from the previous period.
GBP

Revenue (FY, 2016)

48.5 m

Revenue growth (FY, 2015 - FY, 2016), %

12%

Gross profit (FY, 2016)

34.4 m

Gross profit margin (FY, 2016), %

71%

Net income (FY, 2016)

(13.1 m)

EBITDA (FY, 2016)

(10.3 m)

EBIT (FY, 2016)

(12 m)

Market capitalization (31-Oct-2017)

202 m

Closing share price (31-Oct-2017)

0.3

Cash (30-Jun-2016)

23.4 m

EV

178.9 m
Allergy Therapeutics's current market capitalization is £202 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

25.7 m31 m37.8 m40.8 m41.6 m41.3 m39.3 m42 m43.2 m48.5 m

Revenue growth, %

7%3%12%

Cost of goods sold

10.1 m10.9 m13.6 m11.2 m13.2 m13.7 m12 m12 m12.2 m14.1 m

Gross profit

15.7 m20.2 m24.2 m29.6 m28.3 m27.6 m27.3 m30 m31.1 m34.4 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(23.8 m)(20.3 m)(11.8 m)586 k(2.7 m)823 k633 k741 k108 k(13.1 m)

Cash From Operating Activities

20.3 m19.3 m(440 k)1.7 m(2 m)2.9 m2.4 m2.2 m3.1 m(11.8 m)

Cash From Financing Activities

2.7 m18.6 m103 k4.9 m764 k(2.7 m)148 k20.1 m12.5 m

Net Change in Cash

17.7 m3.4 m(2.3 m)4.6 m(3.6 m)(1.4 m)1.4 m1 m20.5 m(792 k)
    GBPY, 2016

    EV/EBITDA

    -17.4 x

    EV/EBIT

    -15 x

    EV/CFO

    -15.1 x

    Revenue/Employee

    130.1 k

    Financial Leverage

    1.9 x
    Show all financial metrics

    Allergy Therapeutics Market Value History

    Allergy Therapeutics's Web-traffic and Trends

    Allergy Therapeutics Company Life and Culture

    You may also be interested in